SEOUL-SEMICONDUCTOR
12.7.2018 15:02:20 CEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a global market leader in LED (light emitting diode) design and manufacturing, announced that a research has shown that its “SunLike ” is an optimized LED for human centric lighting that improves eye health and sleep quality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180712005307/en/
The research team of Biomedical Information Laboratory, Seoul National University College of Medicine in Korea, has reported that using SunLike based lighting, the eye discomfort is significantly reduced and the sleep quality is improved compared to conventional LED lighting users.
The researchers conducted experiments on adults including graduate students at Seoul National University, who spend a lot of time studying at their desk indoors. Each participant was instructed to use SunLike desk lamp and conventional LED lamp for 3 hours before bedtime. The team conducted a questionnaire and analyzed the vital signs of participants recorded during sleep.
Subjective evaluation through questionnaires showed a significant decrease in eye fatigue and a marked improvement in sleep quality. The researchers found that improvement of the feeling of not refreshing after a sleep in the following morning was statistically significant.
As a result of analyzing the measured vital sign, the time it takes to fall asleep is 23% faster and the time to break during sleep was also improved by 43%. Therefore, the research team found that sleep efficiency as an indicator of sleep was significantly improved from 88% to 94%.
“We conclude that these effects are due to the stabilization of the autonomic nervous system rhythm, which is manifested by inactivation of sympathetic nerve and activity of parasympathetic nerve by SunLike based lighting,” said the research team of SNU. “Light affects people’s circadian rhythm. In order to improve biorhythm, we can adjust the light according to time zone and use a light source close to sunlight,” said the research team of SNU.
SunLike is an advanced light source that combines the latest optical and compound semiconductor technology of Seoul Semiconductor and *TRI-R technology, a sunlight spectrum reproduction technology, that is a registered trademark by the Toshiba Materials Co., Ltd. It that lowers blue light peak similar to sunlight spectrum contributes to maintaining a stable human circadian rhythms and enhancing the color clarity of objects.
In addition, as a result of analyzing the blue light emitted by the LED ‘SunLike’, it received Eye Safety Certification for level RG-1, the highest level of safety, from Korea Testing & Research Institute last November. This is the level given to a safe light source without any photobiological hazards.
“Since its launch on June 29th , last year in Frankfurt, Germany, with Toshiba Materials Co., Ltd., SunLike has being supplied to global customers in US, Europe, China and Japan that manufacture home lightings, smart desk stands and lamps. It is also currently working on more than 200 projects for SunLike with customers, suppliers and researchers,” said Minsoo Son, marketing vice president of Seoul Semiconductor. “We will prove SunLike is the innovative LED which adds value for human centric lighting by demonstrating differentiated quality and competitiveness to exceed customers’ expectations.”
*TRI-R, supported by Toshiba Materials, finds in the definition “The light closest to the sun for human well-being” as its original concept. The sun light spectrum is developed by the same company and can be reproduced by a white LED light source technology.
About Seoul Semiconductor
Seoul Semiconductor develops and
commercializes light emitting diodes (LEDs) for automotive, general
illumination, specialty lighting, and backlighting markets. As the
fourth-largest LED manufacturer globally, Seoul Semiconductor holds more
than 12,000 patents, offers a wide range of technologies, and mass
produces innovative LED products such as SunLike – delivering the
world’s best light quality in a next-generation LED enabling
human-centric lighting optimized for circadian rhythms; WICOP – a
simpler structured package-free LED which provides market leading color
uniformity and cost savings at the fixture level, providing high lumen
density and design flexibility; NanoDriver Series – the world’s smallest
24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED
technology developed in 2005, including all AC LED-related technologies
from chip to module and circuit fabrication, as well as multi-junction
technology (MJT); and nPola, a new LED product based on GaN-substrate
technology that achieves more than ten times the output of conventional
LEDs. UCD constitutes a high color gamut display which delivers more
than 90% NTSC. To learn more, visit www.seoulsemicon.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180712005307/en/
Contact:
Seoul Semiconductor Co., Ltd.
Korea and Asia
Jeonghee
Kim
+82-70-4391-8311
+82-10-4843-6303
jeonghee.kim@seoulsemicon.com
Americas
Andrew
Smith
+1 (901) 831-6614
andrew.smith@seoulsemicon.com
China
Vincent
Wu
+86-1391-7898226
vincent.wu@seoulsemicon.com
Europe
Marc
Juarez
+49 89 450 36 90 31
marc.juarez@seoulsemicon.com
Japan
Kohei
Shimooka
+81-80-4668-9710
kohei.shimooka@seoulsemicon.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
